{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T21:58:08Z","timestamp":1771970288428,"version":"3.50.1"},"reference-count":66,"publisher":"Radcliffe Medical Media Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p\/>","DOI":"10.15420\/icr.2017:26:1","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T11:47:07Z","timestamp":1526644027000},"page":"1","source":"Crossref","is-referenced-by-count":9,"title":["Anticoagulant Therapy For Acute Coronary Syndromes"],"prefix":"10.15420","author":[{"given":"Eunice NC","family":"Onwordi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr","family":"Gamal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azfar","family":"Zaman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6096","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","unstructured":"1. Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015;36:1163-70.","journal-title":"Eur Heart J"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJM199201303260506","article-title":"The pathogenesis of coronary artery disease and the acute coronary syndromes (2)","volume":"326","author":"Fuster","year":"1992","unstructured":"2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992;326:310-8.","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. De Caterina R, Goto S. Targeting thrombin long-term after an acute coronary syndrome: opportunities and challenges. Vasc Pharmacol 2016 81:1-14.","DOI":"10.1016\/j.vph.2016.03.003"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","unstructured":"4. Roffi M, Patrono C, Collet JP, Mueller C, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267-315.","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1136\/hrt.82.3.269","article-title":"Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction","volume":"82","author":"Arbustini","year":"1999","unstructured":"5. Arbustini E, Dal Bello P, Morbini P, et al. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart 1999;82:269-72.","journal-title":"Heart"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1136\/heart.83.3.361","article-title":"The pathophysiology of acute coronary syndromes","volume":"83","author":"Davies","year":"2000","unstructured":"6. Davies MJ. The pathophysiology of acute coronary syndromes. Heart 2000;83:361-6.","journal-title":"Heart"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1056\/NEJM198308183090703","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina","volume":"309","author":"Lewis","year":"1983","unstructured":"7. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983;309:396-403.","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin or both to treat unstable angina","volume":"319","author":"Th\u00e9roux","year":"1988","unstructured":"8. Th\u00e9roux P, Ouimet H, McCans J, et al. Aspirin, heparin or both to treat unstable angina. N Engl J Med 1988;319:1105-11.","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease","volume":"337","author":"Cohen","year":"1997","unstructured":"9. Cohen M, Demers C, Gurfinkel EP, et al. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","unstructured":"10. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial Investigators. Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.","DOI":"10.1056\/NEJM199805213382102"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJM200106213442501","article-title":"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb\/IIIa inhibitor tirofiban","volume":"344","author":"Cannon","year":"2001","unstructured":"12. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb\/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Cannon CP, Braunwald E. Time to reperfusion: the critical modulator in thrombolysis and primary angioplasty. J Thromb Thrombolysis 1996;3:117-25.","DOI":"10.1007\/BF00132404"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jacc.2007.10.040","article-title":"Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point","volume":"51","author":"Ndrepepa","year":"2008","unstructured":"14. Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008;51:690-7.","journal-title":"J Am Coll Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1161\/ATVBAHA.107.155952","article-title":"Intrinsic pathway of coagulation and arterial thrombosis","volume":"27","author":"Gailani","year":"2007","unstructured":"15. Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 2007;27:2507-13.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.15420\/icr.2011.9.2.94","article-title":"Current antithrombotic therapy in patients with acute coronary syndromes undergoing percutaneous coronary interventions","volume":"9","author":"Pesarini","year":"2014","unstructured":"16. Pesarini, Ariotti, Ribichini F. Current antithrombotic therapy in patients with acute coronary syndromes undergoing percutaneous coronary interventions. Interv Cardiol 2014;9:94-101.","journal-title":"Interv Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","article-title":"Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis","volume":"355","author":"Eikelboom","year":"2000","unstructured":"17. Eikelboom JW, Anand SS, Malmberg K et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355:1936-42.","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.jacc.2012.03.010","article-title":"Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score","volume":"59","author":"Genereux","year":"2012","unstructured":"18. Genereux P, Palmerini T, Caixeta A, et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score. J Am Coll Cardiol 2012;59:2165-74.","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1161\/01.CIR.89.1.81","article-title":"Antithrombotic Therapy in Acute Coronary Syndromes Research Group","volume":"89","author":"Cohen","year":"1994","unstructured":"19. Cohen M, Adams PC, Parry, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994;89:81-8.","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0140-6736(90)92336-G","article-title":"Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease","volume":"336","author":"Group","year":"1990","unstructured":"20. RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-30.","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Th\u00e9roux P, Waters D, Qiu S, et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993;88(5 pt 1):2045-8.","DOI":"10.1161\/01.CIR.88.5.2045"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Steg PG, Mehta S, Xavier D et al. Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA\/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux. Am Heart J 2010;160:1029-34, 1034.e1.","DOI":"10.1016\/j.ahj.2010.07.037"},{"key":"ref22","unstructured":"23. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-619."},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Silvain J, Beygui F, Barthelemy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ 2012;344:e553.","DOI":"10.1136\/bmj.e553"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-molecular-weight heparins","volume":"337","author":"Weitz","year":"1997","unstructured":"25. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-98.","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Garcia DA, Baglin TP, Weitz J, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e24S-43S.","DOI":"10.1378\/chest.11-2291"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","unstructured":"27. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.ehj.2004.06.028","article-title":"Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial","volume":"25","author":"de Lemos","year":"2004","unstructured":"28. de Lemos JA, Blazing MA, Wiviott SD, et al. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. Eur Heart J 2004;25:1688-94.","journal-title":"Eur Heart J"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST- segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.","DOI":"10.1001\/jama.292.1.45"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0140-6736(11)60876-3","article-title":"Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial","volume":"378","author":"Montalescot","year":"2011","unstructured":"30. Montalescot G, Zeymur U, Silvain J et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet 2011;378:693-703.","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1093\/eurheartj\/ehm224","article-title":"Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis","volume":"28","author":"Murphy","year":"2007","unstructured":"31. Murphy SA, Gibson CM, Morrow DA, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 2007;28:2077-86.","journal-title":"Eur Heart J"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0140-6736(01)05775-0","article-title":"Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction","volume":"358","author":"of the Safety","year":"2001","unstructured":"32. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-3.","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1161\/01.CIR.0000081659.72985.A8","article-title":"Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the pre-hospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction","volume":"108","author":"Wallentin","year":"2003","unstructured":"33. Wallentin L, Goldstein P, Armstrong PW et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the pre-hospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003;108:135-42.","journal-title":"Circulation"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/eurheartj\/ehm179","article-title":"Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis","volume":"28","author":"Giraldez","year":"2007","unstructured":"34. Giraldez RR, Nicolau JC, Corbalan R, et al. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis. Eur Heart J 2007;28:1566-73.","journal-title":"Eur Heart J"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/eurheartj\/ehm081","article-title":"unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25","volume":"28","author":"White","year":"2007","unstructured":"35. White HD, Braunwald E, Murphy SA, et al. Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. Eur Heart J 2007;28:1066-71.","journal-title":"Eur Heart J"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jcin.2009.11.012","article-title":"Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)","volume":"3","author":"Montalescot","year":"2010","unstructured":"36. Montalescot G, Ellis SG, de Belder MA, et al. Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). JACC Cardiovasc Interv 2010;3:203-12.","journal-title":"JACC Cardiovasc Interv"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1111\/j.1538-7836.2011.04445.x","article-title":"unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis","volume":"9","author":"Navarese","year":"2011","unstructured":"37. Navarese EP, De Luca G, Castriota F, et al. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost 2011;9:1902-15.","journal-title":"J Thromb Haemost"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1161\/01.CIR.103.5.658","article-title":"Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris","volume":"103","author":"Collet","year":"2001","unstructured":"38. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-63.","journal-title":"Circulation"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/ccd.10726","article-title":"Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study","volume":"61","author":"Martin","year":"2004","unstructured":"39. Martin JL, Fry ET, Sanderink GJ, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv 2004;61:163-70.","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.","DOI":"10.1001\/jama.292.1.45"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","unstructured":"41. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","unstructured":"42. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITONTIMI 38): double-blind, randomised controlled trial","volume":"373","author":"Montalescot","year":"2009","unstructured":"43. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITONTIMI 38): double-blind, randomised controlled trial. Lancet 2009;373:723-31.","journal-title":"Lancet"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/j.jacc.2004.02.051","article-title":"A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study","volume":"43","author":"Simoons","year":"2004","unstructured":"44. Simoons ML, Bobbink IW, Boland J, et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol 2004;43:2183-90.","journal-title":"J Am Coll Cardiol"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45. Mehta SR, Steg PG, Granger CB, et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation 2005; 22;111:1390-7.","DOI":"10.1161\/01.CIR.0000158485.70761.67"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"46. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-76.","DOI":"10.1056\/NEJMoa055443"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jacc.2009.03.062","article-title":"Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb\/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial","volume":"54","author":"Jolly","year":"2009","unstructured":"47. Jolly SS, Faxon DP, Fox KA, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb\/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. J Am Coll Cardiol 2009;54:468-76.","journal-title":"J Am Coll Cardiol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1001\/jama.2015.517","article-title":"Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction","volume":"313","author":"Szummer","year":"2015","unstructured":"48. Szummer K, Oldgren J, Lindhagen L, et al. Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. JAMA 2015;313:707-16.","journal-title":"JAMA"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","unstructured":"49. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295:1519-30.","journal-title":"JAMA"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/eurheartj\/ehm616","article-title":"The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial","volume":"29","author":"Peters","year":"2008","unstructured":"50. Peters RJ, Joyner C, Bassand JP, et al. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur Heart J 2008;29:324-31.","journal-title":"Eur Heart J"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1161\/01.CIR.91.6.1659","article-title":"GUSTO-I Investigators","volume":"91","author":"Lee","year":"1995","unstructured":"51. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation 1995;91:1659-68.","journal-title":"Circulation"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","unstructured":"52. Lincoff AM, Bittl JA, Harrington RA, et al. REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-63.","journal-title":"JAMA"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","unstructured":"53. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-16.","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0140-6736(07)60450-4","article-title":"Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial","volume":"369","author":"Stone","year":"2007","unstructured":"54. Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. Lancet 2007;369:907-19.","journal-title":"Lancet"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1001\/jama.298.21.2497","article-title":"Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial","volume":"298","author":"Stone","year":"2007","unstructured":"55. Stone GW, Ware JH, Bertrand ME, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 2007;298:2497-506.","journal-title":"JAMA"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.jacc.2007.12.052","article-title":"Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial","volume":"51","author":"White","year":"2008","unstructured":"56. White HD, Chew DP, Hoekstra JW, et al. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008;51:1734-41.","journal-title":"J Am Coll Cardiol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","article-title":"Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction","volume":"365","author":"Kastrati","year":"2011","unstructured":"57. Kastrati A, Neumann FJ, Schulz S, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011;365:1980-9.","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1056\/NEJMoa0802944","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention","volume":"359","author":"Kastrati","year":"2008","unstructured":"58. Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008;359:688-96.","journal-title":"N Engl J Med"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/S0140-6736(01)06887-8","article-title":"Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial","volume":"358","author":"White","year":"2001","unstructured":"59. White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001;358:1855-63.","journal-title":"Lancet"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1507854","article-title":"Bivalirudin or unfractionated heparin in acute coronary syndromes","volume":"373","author":"Valgimigli","year":"2015","unstructured":"60. Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 2015;373:997-1009.","journal-title":"N Engl J Med"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial","volume":"384","author":"Shahzad","year":"2014","unstructured":"61. Shahzad A, Kemp E, Mars C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014;384:1849-58.","journal-title":"Lancet"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jacc.2013.09.027","article-title":"Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI Trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction)","volume":"63","author":"Stone","year":"2014","unstructured":"62. Stone G, Clayton T, Deliargyris E, et al. Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI Trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). J Am Coll Cardiol 2014;63:15-20.","journal-title":"J Am Coll Cardiol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","unstructured":"63. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708.","journal-title":"N Engl J Med"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","unstructured":"64. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.","journal-title":"N Engl J Med"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","unstructured":"65. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781-9.","journal-title":"Eur Heart J"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/jama.2013.277165","article-title":"Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial","volume":"310","author":"Steg","year":"2013","unstructured":"66. Steg PG, Mehta SR, Pollack CV Jr, et al. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. JAMA 2013;310:1145-55.","journal-title":"JAMA"}],"container-title":["Interventional Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.icrjournal.com\/articles\/anticoagulant-therapy-acute-coronary-syndromes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T13:33:50Z","timestamp":1598535230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.icrjournal.com\/articles\/anticoagulant-therapy-acute-coronary-syndromes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":66,"alternative-id":["icr.2017:26:1"],"URL":"https:\/\/doi.org\/10.15420\/icr.2017:26:1","relation":{},"ISSN":["1756-1477"],"issn-type":[{"value":"1756-1477","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}